Hazem Mohamed Salamah

Hazem Mohamed Salamah

Auto-generated profile, based on publicly available information

Hazem Mohamed Salamah

Faculty of Medicine, Zagazig University, Zagazig, Egypt

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2024 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
HSHazem Mohamed Salamah
Hazem Mohamed Salamah
AMAhmed Marey
Ahmed Marey
MAMohamed Abugdida
Mohamed Abugdida
KAKhaled Alsayed Abualkhair
Khaled Alsayed Abualkhair
SESalem Elshenawy
Salem Elshenawy
ASAndleeb Sherazi
Andleeb Sherazi
Background: Prediabetes is a condition preceding the development of diabetes and is associated with an increased risk of a number of complications. The primary mode of management is thought to be lifestyle modification. Pharmacological therapy, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), were not well addressed in the literature and were only evaluated in trials as secondary and exploratory outcomes with a limited sample size. Here, GLP-1RAs are evaluated as a comprehensive therapy approach for patients with prediabetes. Methods: A comprehensive search of Web of Science, SCOPUS, PubMed, and Cochrane was performed on May 5, 2023, to retrieve randomized controlled trials (RCTs) comparing the effect of GLP-1RAs to placebo and/or lifestyle modification on prediabetes reversion to normoglycemia, prevention of overt diabetes, glycemic control, anthropometric parameters, and lipid profiles. Review Manager (RevMan) version 5.4 was used. The quality of RCTs was assessed using the revised version of the Cochrane Risk of Bias Tool. GRADE was performed to evaluate the certainty of evidence. Results: Twelve trials involving 2903 patients in the GLP-1RAs group and 1413 in the control group were included in the meta-analysis. Low quality of evidence revealed that GLP-1RAs significantly increased the incidence of prediabetes reversion to the normoglycemic state [RR = 1.76, 95% CI (1.45, 2.13), P < 0.00001] and moderate quality of evidence showed that GLP-1RAs significantly prevented new-onset diabetes [RR = 0.28, 95% CI (0.19, 0.43), P < 0.00001]. Significant reductions in HbA1c, fasting plasma glucose, body weight, waist circumference, triglycerides, and LDL were observed in the GLP-1RAs arm (P < 0.05). However, higher incidences of gastrointestinal disorders were reported in the GLP-1RAs group (P < 0.05). Conclusions: GLP-1RAs combined with lifestyle modification proved to be a more effective therapy for managing prediabetic patients than lifestyle modification alone, with a tolerable safety profile. Future guidelines should consider GLP-1RAs as an adjunct to lifestyle modification in the management of prediabetic patients to provide better management and improve treatment adherence.

4 March 2024 in Discover Water
Verified
Journal Article
Open access
PDF file
EMEmery Manirambona
Emery Manirambona
DIDon Eliseo Lucero-Prisno III
Don Eliseo Lucero-Prisno III
DSDeborah Oluwaseun Shomuyiwa
Deborah Oluwaseun Shomuyiwa
SDSalomey Asaah Denkyira
Salomey Asaah Denkyira
Okesanya John OlalekanOkesanya John Olalekan
Okesanya John Olalekan
AEAniekan Michael Ekpenyong
Aniekan Michael Ekpenyong
Curbing infectious diseases has been a significant challenge worldwide, with existing conventional surveillance systems presenting gaps in providing timely and spatial information, which undermines prevention and control. This has propelled the use of Wastewater-Based surveillance (WBS), a valuable tool for infectious disease surveillance able to detect early infectious diseases among asymptomatic, pre-symptomatic, symptomatic, and post-symptomatic individuals. Despite the global attention and the contribution of WBS in monitoring the COVID-19 pandemic, its use in the African continent is still stunted, which may hamper the early detection, monitoring, prevention, and response to outbreaks. Africa can benefit from WBS, deemed to be quick, cost-effective, providing timely data to ensure early report of the presence of a high-consequence infectious pathogen and devise timely protective measures at a population-level perspective. In addition, considering its inclusivity in providing an overall burden of infectious agents representing the population even in areas with limited resources, wastewater surveillance is important in tackling health disparities. Therefore, it is crucial to overcome challenges related to implementing surveillance in Africa. This can be achieved by providing adequate investments for surveillance efforts, establishing modern infrastructure to enhance wastewater drainage, enhancing the healthcare workforce through training, improving healthcare infrastructure and equipment, and utilising digital health solutions. Collaborative efforts on both local and global scales are crucial for developing effective health policies, and a robust research capacity within the continent is crucial.

25 October 2022 in EXPLORE
Verified
Journal Article
Closed access
HSHazem Mohamed Salamah
Hazem Mohamed Salamah
EEEsraa Elsayed
Esraa Elsayed
ABAml M. Brakat
Aml M. Brakat
KAKhaled Alsayed Abualkhair
Khaled Alsayed Abualkhair
MHMohamed Alaa Hussein
Mohamed Alaa Hussein
IAIbrahim Abdelmonaem Abdelhaleem
Ibrahim Abdelmonaem Abdelhaleem

22 December 2023 in Archives of orthopaedic and trauma surgery
Verified
Journal Article
Open access
PDF file
HSHazem Mohamed Salamah
Hazem Mohamed Salamah
KAKhaled Alsayed Abualkhair
Khaled Alsayed Abualkhair
SKSara K. Kamal
Sara K. Kamal
HMHazem A. Mohamed
Hazem A. Mohamed
AAAhmad Alkheder
Ahmad Alkheder
HEHany Elbardesy
Hany Elbardesy
Introduction: Bisphosphonates (BPs) are one of the most often used drugs to lower fracture risk in osteoporosis patients; nonetheless, BPs have been linked to atypical femoral fracture (AFF). Teriparatide (TPTD) is a parathyroid hormone analogue and anabolic drug that may accelerate fracture repair. TPTD has been considered as a possible treatment for AFF, particularly those caused by BP use. We evaluate the effect of TPTD on AFF in this systematic review and meta-analysis. Materials and methods: A thorough search of: Web of Science, Scopus, PubMed, and Cochrane was conducted on August 2, 2023. Trials evaluating the effect of TPTD on the incidence of: complete bone healing, non-union, early and delayed bone union, progression of incomplete AFF to complete AFF, and time to bone union were included. Using Review Manager (RevMan) version 5.4, the risk ratio (RR) and mean difference (MD) with the corresponding 95% confidence interval (CI) were estimated for dichotomous and continuous outcomes, respectively. The Newcastle–Ottawa Scale was used to assess the quality of studies. Results: Eight studies met the eligibility criteria and were included in our analysis. TPTD significantly increased the incidence of early bone union (RR = 1.45, 95% CI [1.13, 1.87], P = 0.004) and time to bone union (MD = −1.56, 95% CI [−2.86, −0.26], P = 0.02) compared to the control group. No significant differences were observed in terms of complete bone healing (RR = 1.09, 95% CI [0.99, 1.13], P = 0.12), non-union (RR = 0.48, 95% CI [0.22, 1.04], P = 0.06), and progression of incomplete AFF to complete AFF (RR = 0.27, 95% CI [0.04, 1.97], P = 0.19). Conclusions: TPTD is an effective therapy for enhancing and hastening healing following AFF, particularly in postoperative settings. Future large randomized clinical trials are needed to confirm or dispute the results.

22 March 2025 in Heart & Lung
Verified
Journal Article
Closed access
SRShree Rath
Shree Rath
MAMohamed R. Abdelraouf
Mohamed R. Abdelraouf
WHWajeeh Hassan
Wajeeh Hassan
QMQasim Mehmood
Qasim Mehmood
MAMuhammad Ansab
Muhammad Ansab
RARaheel Ahmed
Raheel Ahmed

3 November 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HSHazem Mohamed Salamah
Hazem Mohamed Salamah
AMAhmed Marey
Ahmed Marey
EEEsraa Elsayed
Esraa Elsayed
MHMohammed Tarek Hasan
Mohammed Tarek Hasan
AMAbdelrahman Mahmoud
Abdelrahman Mahmoud
MAMohamed Abd-Elgawad
Mohamed Abd-Elgawad
Polyethylene glycol loxenatide (PEX168) is a novel glucagon-like peptide-1 receptor agonist with a longer half-life developed by modifying the chemical structure of exenatide. This study aims to assess the efficacy and safety of PEX168 and determine the best dose. We searched PubMed, Scopus, Cochrane Library, and Web of Science databases from inception to April 25, 2023, for randomized controlled trials (RCTs) comparing PEX168 therapy alone or in combination with metformin versus other therapies. We used the risk ratio (RR) for dichotomous outcomes and the mean difference (MD) for continuous outcomes, both with 95% confidence intervals (CI). Six RCTs, including 1248 participants, were included. PEX168 added to metformin was significantly better than metformin alone regarding fasting blood glucose (MD = −1.20, 95% CI (−1.78, − 0.62), p < 0.0001), HbA1c (MD = −1.01, 95% CI (−1.48, − 0.53), p < 0.0001), and postprandial glycemia (MD = −1.94, 95% CI (−2.99, − 0.90), p = 0.0003). Similarly, for glycemic control, PEX168 monotherapy was superior to placebo (P < 0.05). No significant effects were noticed in terms of triglycerides, low-density lipoprotein, or high-density lipoprotein (p > 0.05). Body weight was significantly reduced in obese diabetic patients receiving PEX168 compared to the control group (MD = −5.46, 95% CI (−7.90, − 3.01), p < 0.0001) but not in non-obese patients (MD = 0.06, 95% CI (−0.47, 0.59), p = 0.83). People who received PEX168 alone or with metformin showed more common gastrointestinal adverse effects, especially nausea and vomiting (p < 0.05). PEX168 100, 200, and 300 ug monotherapy demonstrated comparable safety and diabetes control to metformin, but when combined with metformin, PEX168 100 and 200 ug showed significant effects on diabetes control; however, only the latter showed a significantly higher incidence of nausea and vomiting (p < 0.05). PEX168 could be a viable option for treating diabetic patients whose metformin control is inadequate or who cannot tolerate metformin. PEX168 at 100 ug in combination with metformin was found to be safe and more effective compared to metformin; however, due to the small number of trials included, these findings should be interpreted with caution, and additional trials are required.